Cannabigerol Emerges as a Laboratory Lead Against MRSA
A 2020 study from McMaster University identified cannabigerol (CBG), a non-intoxicating cannabinoid, as a promising starting point for developing treatments against methicillin-resistant Staphylococcus aureus (MRSA). The research, published in ACS Infectious Diseases, examined 18 commercially available cannabinoids and found antibacterial activity across the compounds tested, although CBG showed the strongest results in several experiments.
MRSA is resistant to multiple antibiotics and can cause infections ranging from skin disease to pneumonia and bloodstream infections. Like many bacteria, it can also form biofilms—organized communities of cells protected by a surrounding matrix. Biofilms can make infections harder to eradicate and can develop on tissues and medical devices. The U.S. Centers for Disease Control and Prevention’s MRSA overview provides additional background on the pathogen and its clinical risks.
In laboratory tests, CBG inhibited MRSA’s ability to form biofilms and could damage established biofilms and bacterial cells that had entered a persistent, antibiotic-tolerant state. In one assay, concentrations as low as 0.5 micrograms per milliliter reduced biofilm formation by about half. The researchers found that CBG acts on the bacterial cytoplasmic membrane, disrupting a structure essential to the survival of Gram-positive bacteria such as MRSA.
The team then tested CBG in a mouse model of systemic MRSA infection. Its effect was comparable to that of vancomycin in that experimental setting, an encouraging result but not evidence that CBG is ready for use in people. Animal studies do not establish human safety, dosing, effectiveness, or suitability for treating clinical infections, and the study did not constitute a clinical trial.
CBG was less effective on its own against drug-resistant Gram-negative bacteria such as Escherichia coli. These organisms have an additional outer membrane that can prevent cannabinoids from reaching their primary target. When researchers used polymyxin B to permeabilize that outer membrane, CBG was able to work against multidrug-resistant Gram-negative pathogens in laboratory experiments.
The findings therefore point to two possible development strategies: using CBG or related compounds directly against some Gram-positive infections, or pairing cannabinoids with other drugs to improve their activity against Gram-negative bacteria. However, CBG also showed toxicity toward some mammalian cells, leaving researchers with a narrow therapeutic window to improve.
As the McMaster research team noted, the compound is better understood as a lead for drug discovery than as a finished medicine. Further work would need to improve its selectivity for bacteria, establish how it behaves in the body, assess resistance development, and demonstrate safety and efficacy in human clinical trials. The broader urgency is clear: the World Health Organization identifies antimicrobial resistance as a major global health threat, but a promising laboratory result is only an early step toward a usable antibiotic.
